Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Firebrick Pharma Limited ( (AU:FRE) ) has shared an update.
Firebrick Pharma Limited has announced a change in its auditing firm, transitioning from BDO Audit Pty Ltd to Criterion Audit Pty Ltd effective December 1, 2025. This change aims to align audit services with the company’s size and nature, resulting in cost reductions. The appointment of the new auditor will be ratified at the next Annual General Meeting in November 2026.
More about Firebrick Pharma Limited
Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has introduced Nasodine® Nasal Spray into markets such as the United States, Singapore, and Fiji & South Pacific, with further expansion expected in the Philippines in 2026. Additionally, Firebrick is preparing to launch Nasodine Throat Spray in Singapore.
Average Trading Volume: 92,051
Technical Sentiment Signal: Sell
Current Market Cap: A$15.6M
For an in-depth examination of FRE stock, go to TipRanks’ Overview page.